Marques et al. recently evaluated the effects of PCSK9 inhibition on inflammatory state, endothelial dysfunction and cardiovascular outcomes in patients with familiar hypercholesterolemia treated with maximum statin doses and, if necessary, with ezetimibe [41]. Here, PCSK9 is linked to endothelial dysfunction.